Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
As technology has advanced, rare diseases have been met with therapies that target the cause of the condition, enabling the global market for orphan drugs to reach an expected $262bn by 2024.
Medcision has started pushing its cell therapy thawing technology through an early adopter scheme designed to encourage adoption by firms with candidates in trials.
Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.
The global contract and manufacturing organization (CDMO) announced the construction at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site.
GE Healthcare has teamed up with the Canadian Government and the Toronto-based Centre for Commercialization of Regenerative Medicine develop cell therapy manufacturing technologies.
Almac will transfer its custom peptide manufacturing business to a site at the Edinburgh Technopole business park in Scotland’s capital in a £3.5m move designed to expand capacity.
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
Parker Domnick Hunter has launched a new filtration tech for antibody makers that combines know-how from several firms acquired over the past few years.
Over the last decade single-use technologies have moved into manufacturing scales and are increasingly being deployed worldwide, according to Thermo Fisher Scientific.
ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.
The implementation of single use technology in the biopharmaceutical fill and finish process has seen a massive uptick recently because of better industry understanding, according to Pall’s Bruce Rawlings.
EMD Millipore premiered a new single-use bioreactor at Interphex 2012, claiming the new design addresses industry demand for ease of use and flexibility.
How have single-use technologies changed drug production? How do you dispose of a disposable technology? What will drive the market going forward? EMD Millipore answered these questions and more at Interphex 2011.
West Pharmaceutical Services and Japan’s Daikyo Seiko team on container technology they claim will help drugmakers ensure consistency during scale-up operations
DSM Biologics says combining its XD platform with newly-acquired Rhobust chromatography platform will create high yield, low cost bio-manufacturing option.
The contract manufacturing market for biologicals will more than
double over the next six years, but production costs are higher
than necessary because 'downstream' processing is being ignored.
Capsule technology company BioProgress has reported its first set
of interim results since becoming an AIM-listed company, as well as
a distribution deal with Hoefliger.
